Lv11
50 积分 2023-01-10 加入
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
3小时前
已关闭
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
3小时前
已关闭
CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity
2个月前
已完结
The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity
2个月前
已完结
1190 A novel ‘2+1’bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS
2个月前
已完结
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting
2个月前
已完结
A Guide to Rational Dosing of Monoclonal Antibodies
3个月前
已完结
A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
3个月前
已完结
Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
3个月前
已完结
Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route
3个月前
已完结
皖公网安备34019202002308
